A bioclinical prognostic model using MYC and BCL2 predicts outcome in relapsed/refractory diffuse large B-cell lymphoma

The objective of this study was to create a bioclinical model, based on clinical and molecular predictors of event-free and overall survival for relapsed/refractory diffuse large B-cell lymphoma patients treated on the Canadian Cancer Trials Group (CCTG) LY12 prospective study. In 91 cases, sufficie...

Descripción completa

Detalles Bibliográficos
Autores principales: Bosch, Mark, Akhter, Ariz, Chen, Bingshu E., Mansoor, Adnan, Lebrun, David, Good, David, Crump, Michael, Shepherd, Lois, Scott, David W., Stewart, Douglas A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5792273/
https://www.ncbi.nlm.nih.gov/pubmed/29097500
http://dx.doi.org/10.3324/haematol.2017.179309

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5792273/
https://www.ncbi.nlm.nih.gov/pubmed/29097500
http://dx.doi.org/10.3324/haematol.2017.179309

Ejemplares similares